Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2016 1
2017 2
2018 3
2019 2
2020 2
2021 3
2022 7
2023 11
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

33 results

Results by year

Filters applied: . Clear all
Page 1
Inhibition of stearoyl-CoA desaturase 1 (SCD1) enhances the antitumor T cell response through regulating β-catenin signaling in cancer cells and ER stress in T cells and synergizes with anti-PD-1 antibody.
Katoh Y, Yaguchi T, Kubo A, Iwata T, Morii K, Kato D, Ohta S, Satomi R, Yamamoto Y, Oyamada Y, Ouchi K, Takahashi S, Ishioka C, Matoba R, Suematsu M, Kawakami Y. Katoh Y, et al. Among authors: ouchi k. J Immunother Cancer. 2022 Jul;10(7):e004616. doi: 10.1136/jitc-2022-004616. J Immunother Cancer. 2022. PMID: 35793868 Free PMC article.
Cancer Pain Management in Patients Receiving Inpatient Specialized Palliative Care Services.
Tagami K, Chiu SW, Kosugi K, Ishiki H, Hiratsuka Y, Shimizu M, Mori M, Kubo E, Ikari T, Arakawa S, Eto T, Shimoda M, Hirayama H, Nishijima K, Ouchi K, Shimoi T, Shigeno T, Yamaguchi T, Miyashita M, Morita T, Inoue A, Satomi E. Tagami K, et al. Among authors: ouchi k. J Pain Symptom Manage. 2024 Jan;67(1):27-38.e1. doi: 10.1016/j.jpainsymman.2023.09.015. Epub 2023 Sep 18. J Pain Symptom Manage. 2024. PMID: 37730073
A multi-institutional observational study evaluating the incidence and the clinicopathological characteristics of NeoRAS wild-type metastatic colorectal cancer.
Osumi H, Takashima A, Ooki A, Yoshinari Y, Wakatsuki T, Hirano H, Nakayama I, Okita N, Sawada R, Ouchi K, Fukuda K, Fukuoka S, Ogura M, Takahari D, Chin K, Shoji H, Kato K, Ishizuka N, Boku N, Yamaguchi K, Shinozaki E. Osumi H, et al. Among authors: ouchi k. Transl Oncol. 2023 Sep;35:101718. doi: 10.1016/j.tranon.2023.101718. Epub 2023 Jun 24. Transl Oncol. 2023. PMID: 37364334 Free PMC article.
Prevalence of opioid-induced adverse events across opioids commonly used for analgesic treatment in Japan: a multicenter prospective longitudinal study.
Hiratsuka Y, Tagami K, Inoue A, Sato M, Matsuda Y, Kosugi K, Kubo E, Natsume M, Ishiki H, Arakawa S, Shimizu M, Yokomichi N, Chiu SW, Shimoda M, Hirayama H, Nishijima K, Ouchi K, Shimoi T, Shigeno T, Yamaguchi T, Miyashita M, Morita T, Satomi E. Hiratsuka Y, et al. Among authors: ouchi k. Support Care Cancer. 2023 Oct 16;31(12):632. doi: 10.1007/s00520-023-08099-2. Support Care Cancer. 2023. PMID: 37843639 Free PMC article.
Phase II study of biweekly cetuximab plus mFOLFOX6 or mFOLFIRI as second-line treatment for metastatic colorectal cancer and exploratory analysis of associations between DNA methylation status and the efficacy of the anti-EGFR antibody: T-CORE1201.
Takahashi S, Ouchi K, Sakamoto Y, Mori T, Shimodaira H, Takahashi M, Ohori H, Kudo C, Takahashi Y, Imai H, Akiyama S, Takahashi M, Suto T, Murakawa Y, Oishi T, Isobe H, Okada Y, Kawai S, Yoshioka T, Sato T, Shindo Y, Sugiyama S, Komine K, Chiba N, Okita A, Yamaguchi T, Ishioka C. Takahashi S, et al. Among authors: ouchi k. J Gastrointest Oncol. 2023 Apr 29;14(2):676-691. doi: 10.21037/jgo-22-862. Epub 2023 Mar 27. J Gastrointest Oncol. 2023. PMID: 37201044 Free PMC article.
FOLFIRI Chemotherapy for Patients With Metastatic Urachal Carcinoma.
Taniguchi SH, Komine K, Takenaga N, Yoshida Y, Sasaki K, Kawamura Y, Kasahara Y, Ouchi K, Imai H, Saijo K, Shirota H, Takahashi M, Ishioka C. Taniguchi SH, et al. Among authors: ouchi k. Anticancer Res. 2023 Dec;43(12):5699-5704. doi: 10.21873/anticanres.16775. Anticancer Res. 2023. PMID: 38030182
33 results